Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Search Results

Title:
G0265 A Phase II Evaluation of ADXS11-001 in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix
Protocol Number:
G0265
Phase:
Phase II
Physician:
Deborah Armstrong
Purpose:
The purpose of this study is to find out if ADXS11-001 works in treating recurrent or persistent cancer of the cervix and to find out what side effects are caused by this drug. ADXS11-001 is intended to stimulate the immune system to respond to the human papillomavirus (HPV) and cervical cancer. HPV comes in over 100 different types; persistent HPV infections are known to be the major risk factor for invasive cervical cancer. This experimental drug is a modified and weakened version of a well-known bacterium called Listeria monocytogenes. This bacterium has been shown to stimulate the immune system and as a result, has the potential to be used to treat cancer. ADXS11-001 contains a unique DNA sequence of HPV, which is found in all cervical cancers.
Eligibility:
- persistent or recurrent squamous or non-squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma of the cervix - measurable disease - normal lab values and good performance status - must have had one prior systemic chemotherapy regimen for advanced, metastatic, or recurrent disease - allowed to receive one additional regimen and allowed to receive prior biologic/targeted therapy
Treatment:
This is an all outpatient regimen. Women will receive an IV infusion of ADXS11-001 once every 28 days for a maximum of 3 doses. Women will be closely monitored and required to follow a strict schedule of oral medications at home.
Population:
Adult
Last Update
04/19/2014 04:02 AM
 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer